ArticleCancer medicine2024
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Diagnostic accuracy of contrast-enhanced mammography in evaluating breast cancer response to neoadjuvant therapy: a systematic review and meta-analysis.La Radiologia medica · 2026Pooled it
- Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.Annals of surgical oncology · 2026Article
- Confounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Small Triple-Negative and HER2-Positive Early Breast Cancer: Upfront Surgery or Neoadjuvant Chemotherapy?Cancers · 2026Review
- Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive/HER2-negative breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Early predictive value of calcification on ultrasound and mammography for pathological complete response to neoadjuvant chemotherapy in breast cancer.BMC women's health · 2026Article
- Comparison of Contralateral Breast Background Parenchymal Enhancement on MRI Before and After Neoadjuvant Chemotherapy According to Molecular Subtypes in Unilateral Breast Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Factors associated with locoregional recurrence after neoadjuvant chemotherapy for breast cancer in a safety-net medical center.Breast cancer research and treatment · 2025Article
- Nomograms Integrating MRI-derived Apparent Diffusion Coefficient and Clinicopathologic Features for Prediction of Axillary Lymph Node Metastasis in Breast Cancer.Radiology. Imaging cancer · 2025Article
- Development and validation of a nomogram to predict survival after neoadjuvant chemotherapy in elderly women with triple-negative invasive ductal breast cancer: A SEER population-based study.Saudi medical journal · 2025Article
- Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe investigated the pathologic complete response rates (pCR) and survival outcomes of early breast cancer patients who underwent neoadjuvant chemotherapy (NAC) over 14 years at a French comprehensive cancer center and reported pCR and survival outcomes by tumor subtypes and size.
methodsFrom January 2005 to December 2018, 1150 patients receiving NAC were identified. Correlations between cT stage, breast tumor response, axillary lymph node response, pCR, surgery, and outcomes were assessed. pCR was defined as (ypT0/ypTis) and (ypN0/pN0sn).
resultsA pCR was reached in 31.7% (365/1150) of patients and was strongly associated with tumor subtypes, but not with tumor size (pretreatment cT category). Luminal-B Her2-negative and triple-negative (TN) subtypes, cN1 status, older age, and no-pCR had an independent negative prognostic value. Overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS) were not significantly different for cT0-1 compared to cT2 stages. In Cox-model adjusted on in-breast pCR and pN status, ypN1 had a strong negative impact (OS, RFS, and MFS: HR = 3.153, 4.677, and 6.133, respectively), higher than no in-breast pCR (HR = 2.369, 2.252, and 2.323). A negative impact of no pCR on OS was observed for cN0 patients and TN tumors (HR = 4.972) or HER2-positive tumors (HR = 11.706), as well as in Luminal-B Her2-negative tumors on MFS (HR = 2.223) and for Luminal-A on RFS (HR = 4.465) and MFS (HR = 4.185).
conclusionAchievement of pCR, but not tumor size (pretreatment cT category), has an independent prognostic impact on survival. These results suggest potential NAC benefits in patients with small tumors (<2 cm), even in absence of clinically suspicious lymph nodes. Residual lymph node disease after NAC is the most powerful adverse prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.